Arndt Schottelius, Chief Executive Officer
Professional Overview
Arndt Schottelius is a seasoned pharmaceutical and biotechnology executive with extensive expertise in research and development, strategic leadership, and driving business growth. Currently serving as the Chief Executive Officer of Maxion Therapeutics and the Chief Scientific Officer (CSO) and Member of the Executive Management Board at Affimed, Schottelius brings a wealth of industry experience and a proven track record of success.
Experience Summary
Current Role
As the Chief Executive Officer of Maxion Therapeutics, Schottelius is responsible for defining and executing the company's strategic vision, overseeing day-to-day operations, and fostering a culture of innovation and excellence. In his role as CSO and Executive Management Board member at Affimed, he is instrumental in shaping the company's R&D roadmap and strategy, championing the development of groundbreaking immunotherapies.
Career Progression
Prior to his current roles, Schottelius held several senior positions in the pharmaceutical and biotechnology industry. As the Executive Vice President, Head of R&D, and member of the Executive Management Board at Kymab Ltd, he defined and instituted the company's R&D roadmap and strategy, driving significant business growth. He also served as the Chief Development Officer (CDO) at MorphoSys AG, where he championed the company's transformation into a $2 billion development company. Earlier in his career, Schottelius held roles as the Medical Director of Immunology Tissue Growth & Repair Clinical Development at Genentech and as a Senior Scientist at Bayer Pharmaceuticals.
Academic Background
Schottelius holds a strong academic background, with a focus on the pharmaceutical and biotechnology fields. His educational achievements include a specialized degree from a prestigious institution.
Areas of Expertise
Schottelius' areas of expertise span across several key domains, including:
- Strategic leadership and business development
- R&D roadmap and strategy formulation
- Innovative drug discovery and development
- Immunology and tissue growth and repair
- Clinical development and regulatory affairs
- Cross-functional team management and collaboration
Professional Impact
Throughout his career, Schottelius has made significant contributions to the pharmaceutical and biotechnology industries. His leadership and strategic vision have been instrumental in driving the growth and development of several companies, leading to measurable achievements and industry recognition.
Conclusion
With his extensive experience, proven track record, and multifaceted expertise, Arndt Schottelius is well-positioned to continue making a profound impact in the pharmaceutical and biotechnology sectors. As he navigates his current roles, he remains focused on leveraging his skills and expertise to drive innovation, foster collaborations, and deliver transformative solutions that positively impact the lives of patients.
